The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

Please provide your email address to receive an email when new articles are posted on . Researchers analyzed the results of therapeutic approaches to increase ADAMTS13 levels prior to elective surgery ...

A recent meta-analysis concluded that plasma exchange is the most effective intervention for thrombotic thrombocytopenic purpura and that plasma manipulation offers no additional benefit over simple ...

Investigators said they were able to confirm diagnoses of systemic lupus erythematosus (SLE) and thrombotic thrombocytopenic purpura (TTP) because they took a multidisciplinary approach. Thrombotic ...

Please provide your email address to receive an email when new articles are posted on . Adjuvant low-dose rituximab in combination with plasma exchange and steroids appeared effective for the ...

Investigators said the Mortality in TTP Score (MITS) was effective at characterizing the risk of death in patients hospitalized with thrombotic thrombocytopenic purpura (TTP). The prognostic tool used ...

• The American Red Cross and Blood Systems Incorporated (BSI) would be the manufacturers of INTERCEPT plasma for treatment of TTP upon FDA approval and could provide INTERCEPT plasma to other blood ...

London, UK - Researchers have made a breakthrough in identifying the molecular pathogenesis of thrombotic thrombocytopenic purpura (TTP). They have proven that disruption of an enzyme that cleaves the ...

A first-of-its-kind clinical trial shows that therapeutic plasma exchange (TPE) combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as measured by multi-omic ...

Sanofi announced that the Food and Drug Administration (FDA) has approved Cablivi (caplacizumab-yhdp) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in ...